Sensitive and Selective Bioscreening of the Most Commonly Used Coronavirus Disease Drug, Favipiravir, and Its Co-Administered therapeutic, Meropenem, in Human Plasma.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of separation science"
DOI: 10.1002/jssc.202200332
Abstract: Favipiravir and Meropenem have been concurrently used as directly acting antiviral and antibiotic agents for the treatment of coronavirus disease in human plasma. Accurate and specific reversed phase ultra-performance liquid chromatographic and high performance thin… read more here.
Keywords: human plasma; coronavirus disease; meropenem; favipiravir ... See more keywords
Real‐time monitoring of enzyme‐catalyzed phosphoribosylation of anti‐influenza prodrug favipiravir by time‐lapse nuclear magnetic resonance spectroscopy
Sign Up to like & getrecommendations! Published in 2022 at "NMR in Biomedicine"
DOI: 10.1002/nbm.4888
Abstract: Favipiravir (brand name Avigan), a widely known anti‐influenza prodrug, is metabolized by endogenous enzymes of host cells to generate the active form, which exerts inhibition of viral RNA‐dependent RNA polymerase activity; first, favipiravir is converted… read more here.
Keywords: time; anti influenza; influenza prodrug; spectroscopy ... See more keywords
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Sign Up to like & getrecommendations! Published in 2021 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-021-00517-4
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded RNA virus. Favipiravir is an orally administrable antiviral drug whose mechanism of action is to selectively inhibit… read more here.
Keywords: oxygen; trial; favipiravir; covid ... See more keywords
Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.
Sign Up to like & getrecommendations! Published in 2020 at "Antiviral research"
DOI: 10.1016/j.antiviral.2020.104758
Abstract: BACKGROUND In spite of recurrent and dramatic outbreaks, there are no therapeutics approved against Ebola virus disease. Favipiravir, a RNA polymerase inhibitor active against several RNA viruses, recently demonstrated significant but not complete protection in… read more here.
Keywords: non human; ebola virus; model; bid ... See more keywords
Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs “Remdesivir and Favipiravir”: Green assessment with application to pharmaceutical formulations and human plasma
Sign Up to like & getrecommendations! Published in 2021 at "Microchemical Journal"
DOI: 10.1016/j.microc.2021.107101
Abstract: A great demand for discovering new therapeutic solutions has been considered all over the world for managing the rapidly progressing COVID-19 pandemic. Remdesivir (REM) and Favipiravir (FAV) are introduced as promising newly developed antiviral agents… read more here.
Keywords: pharmaceutical formulations; method; human plasma; densitometric method ... See more keywords
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis
Sign Up to like & getrecommendations! Published in 2022 at "Drug Delivery"
DOI: 10.1080/10717544.2022.2118398
Abstract: Abstract Favipiravir, an RNA-dependent RNA polymerase (RdRp) inhibitor, is used to treat patients infected with influenza virus and most recently with SARS-CoV-2. However, poor accumulation of favipiravir in lung tissue following oral administration has required… read more here.
Keywords: time; stability; solution; favipiravir ... See more keywords
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19
Sign Up to like & getrecommendations! Published in 2021 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofab563
Abstract: Abstract Background Favipiravir is used to treat influenza, and studies demonstrate that it has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods We performed a randomized, open-label, multicenter, phase 2 proof-of-concept trial… read more here.
Keywords: group; day; disease; favipiravir ... See more keywords
Determining the Mutation Bias of Favipiravir in Influenza Virus Using Next-Generation Sequencing
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Virology"
DOI: 10.1128/jvi.01217-18
Abstract: New antiviral drugs are needed as a first line of defense in the event of a novel influenza pandemic. Favipiravir is a broad-spectrum antiviral which is effective against influenza. The exact mechanism of how favipiravir… read more here.
Keywords: mutation bias; influenza; bias; next generation ... See more keywords
22 Favipiravir pharmacokinetics in immunocompromised infants and children with chronic RNA viral infections
Sign Up to like & getrecommendations! Published in 2023 at "Archives of Disease in Childhood"
DOI: 10.1136/archdischild-2023-esdppp.22
Abstract: Introduction Favipiravir selectively inhibits RNA polymerase responsible for single-stranded viral replication. It is licensed for treating influenza and repurposed to treat other diseases such as Ebola and COVID-19. It is metabolised by hepatic aldehyde oxidase… read more here.
Keywords: immunocompromised infants; pharmacokinetics immunocompromised; favipiravir pharmacokinetics; model ... See more keywords
A favipiravir-induced angioedema and urticaria in a COVID-19 patient
Sign Up to like & getrecommendations! Published in 2022 at "Antiviral Therapy"
DOI: 10.1177/13596535221146226
Abstract: Although favipiravir is a promising drug for coronavirus disease 2019, some adverse effects, including skin lesions, have been reported. A 56-year-old female who was prescribed favipiravir by a filiation team following a positive severe acute… read more here.
Keywords: angioedema urticaria; induced angioedema; urticaria covid; favipiravir induced ... See more keywords
Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "PLOS Medicine"
DOI: 10.1371/journal.pmed.1004120
Abstract: Background: Early antiviral treatment is effective for COVID-19 but currently available agents are expensive. Favipiravir is routinely used in many countries, but efficacy is unproven. Antiviral combinations have not been systematically studied. We aimed to… read more here.
Keywords: favipiravir; lopinavir ritonavir; day; placebo ... See more keywords